香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引 致的任何損失承擔任何責任。 Guangdong Marubi Biotechnology Co., Ltd. 廣東丸美生物技術股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求 而刊發，僅用作提供信息予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣 下知悉、接納並向本公司、本公司的聯席保薦人、整體協調人、顧問或包銷團成員表示同意： 本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港公司註冊處處長登記前，本公 司不會向香港公眾人士提出要約或邀請。倘於適當時候向香港公眾人士提出要約或邀請，有意投資者務請 僅依據向香港公司註冊處處長註冊的本公司招股章程作出投資決定；招股章程的文本將於發售期內向公眾 刊發。 (a) ...

（ 於 開 曼 群 島 註 冊 成 立 之 有 限 公 司 ） （股份代號：1872） 自願公告 業務更新 香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 之 內 容 概 不 負 責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部 或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 Guan Chao Holdings Limited 冠 轈 控 股 有 限 公 司 董事會將於適當時候另行刊發公告，以知會股東及本公司潛在投資者有關本集團 業務營運的任何重大發展。 本 公 告 由 冠 轈 控 股 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）自 願 刊 發，旨在向本公司股東（「股東」）及潛在投資者提供本集團最新業務發展情況。 茲提述本公司日期為2025年5月26日及2025年8月4日的公告，內容有關本集團新 開發的美髮產品業務（「該等公告」）。除另有界定者外，本公告所用詞彙與該等公 告所界定者具有相同涵義。 本公司謹此向股東及潛 在投資者提供最新進展，於2025 年9 ...

Market Performance - The Hang Seng Index opened 101 points higher on the 27th, rose 129 points to a high of 25,653 points in the early session, then fell back, and closed down 323 points or 1.3% at 25,201 points [1] - The H-shares Index fell 128 points or 1.4% to close at 9,020 points, and the Hang Seng Tech Index fell 84 points or 1.5% to close at 5,697 points [1] - The total turnover of the market increased to HK$371.376 billion, the highest in nearly four months [1] - A-share market opened slightly higher, the ChiNext Index once rose more than 2%, but all three major indices fell in the afternoon. The Shanghai Composite Index closed down 68 points or 1.8% at 3,800 points, with a turnover of RMB 1.33 trillion; the Shenzhen Component Index closed down 178 points or 1.4% at 12,295 points, with a turnover of RMB 1.84 trillion; the ChiNext Index closed down 18 points or 0.7% at 2,723 points, with a turnover of RMB 878.3 billion [2] - In the US stock market on Wednesday, the Nasdaq rose 45 points or 0.2% to 21,590 points, the S&P 500 Index rose 15 points or 0.2% to 6,481 points, and the Dow Jones Industrial Average rose 147 points or 0.3% to 45,565 points [2] Central Bank Operations - The People's Bank of China conducted RMB 379.9 billion of seven-day reverse repurchase operations on the 27th, with the operating rate remaining unchanged at 1.4%. There were RMB 616 billion of reverse repurchases maturing, resulting in a net withdrawal of RMB 236.1 billion [2] - The central parity rate of the RMB against the US dollar was raised by 80 points to 7.1108 [2] Company Earnings - Ctrip Group - S (09961.HK) reported a turnover of RMB 28.714 billion for the six months ended June this year, up 16.2% year-on-year. Net profit was RMB 9.123 billion, up 12% year-on-year, and non-GAAP net profit was also RMB 9.123 billion, up 12% year-on-year. Earnings per share were RMB 13.82. No dividend was declared [3] - Maogeping (01318.HK) reported revenue of RMB 2.588 billion for the six months ended June, up 31.3% year-on-year; gross profit was RMB 2.179 billion, up 30.2%. Net profit was RMB 670 million, up 36.1%, and earnings per share were RMB 1.37. No dividend was declared [4] - China Mengniu Dairy Company Limited (02319.HK) reported revenue of RMB 41.567 billion for the six months ended June, down 6.9% year-on-year due to the oversupply of raw milk and the slower-than-expected recovery of demand. Net profit was RMB 2.046 billion, down 16.4%, and earnings per share were 52.3 cents. No dividend was declared [4] - People's Insurance Company (Group) of China, Ltd. (01339.HK) reported total operating income of RMB 324.122 billion for the six months ended June this year, up 10.9% year-on-year. Net profit was RMB 26.671 billion, up 14% year-on-year, and earnings per share were RMB 0.6. An interim cash dividend of RMB 0.075 per 10 shares was declared, compared with RMB 0.063 per 10 shares in the same period last year [4] - Innovent Biologics, Inc. (01801.HK) reported revenue of RMB 5.953 billion for the six months ended June this year, up 50.6% year-on-year. It turned from a loss to a profit of RMB 834 million, compared with a loss of RMB 393 million in the same period last year. Earnings per share were RMB 0.51. No dividend was declared. Non-IFRS profit was RMB 1.213 billion, compared with a loss of RMB 160 million last year; non-IFRS EBITDA was RMB 1.413 billion, compared with a loss of RMB 161 million last year [5] - Meituan (03690.HK) reported a profit of RMB 365 million for the second quarter ended June 2025, down 96.8% year-on-year. Non-IFRS adjusted EBITDA was RMB 2.782 billion, down 81.5% year-on-year, and adjusted net profit fell 89% to RMB 1.493 billion. Revenue in the second quarter was RMB 91.84 billion, up 11.7% year-on-year, slightly lower than the forecast range of RMB 92.067 billion to RMB 94.534 billion by 8 brokers [5]

Market Performance - Hang Seng Index (HSI) rose by 62 points or 0.25%, closing at 24,969 points[1] - Shanghai Composite Index increased by 18 points or 0.5%, closing at 3,665 points[1] - S&P 500 gained 72 points or 1.1%, closing at 6,445 points, reaching a new high[2] Economic Indicators - US inflation rate for July remained stable at 2.7%, boosting market expectations for a rate cut in September[2] - People's Bank of China conducted a 7-day reverse repo operation of 114.6 billion yuan at a steady rate of 1.4%[1] Corporate Earnings - China Unicom reported a net profit of 14.484 billion yuan, up 5% year-on-year[5] - China Evergrande received a letter from the stock exchange regarding its failure to meet resumption requirements, leading to delisting[4] - China Resources Land achieved total contract sales of approximately 13.3 billion yuan in July, a year-on-year decrease of 14.2%[3] Currency and Trade - Hong Kong dollar weakened, reaching 7.85 HKD per USD, prompting the Monetary Authority to buy 7.065 billion HKD[2] - US government recorded a budget deficit of 291 billion USD in July, an increase of 47 billion USD compared to last year[3]